SYNCELL today announced that it is participating in the upcoming investor conference, Biotech Showcase 2022, to be held in San Francisco, California from January 10-12, 2022. SYNCELL CEO, Jung-Chi Liao, PhD, will represent SYNCELL during the conference, and will make an in-person presentation. His presentation will also be available on-demand after the conference.

Biotech Showcase has become one of the industry’s leading investor conferences in recent years. The 2022 conference is expected to attract a wide range of business leaders, including notable investors, top-tier executives from major biotech companies, business development teams from various pharmaceutical companies, and many industry experts.

Dr. Liao expressed his excitement about being selected to present at the upcoming Biotech Showcase 2022 “this conference provides a sophisticated networking platform for executives and investors to interact. We expect to have many one-on-one meetings with prospective investors and potential business partners, as well as network with hundreds of peers interested in our part of the industry.”

About Biotech Showcase
Biotech Showcase is an investor conference and provides a key platform where companies can showcase their innovative assets and build their profile with potential investors and strategic partners. The conference aims to drive the future of drug development and is devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives all in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this important week which sets the tone for the coming year. Now in its fourteenth year, this rapidly growing conference features multiple levels of presenting companies, plenary sessions, workshops, networking, and endless opportunities to schedule one-on-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase attendees include investors in private and public companies, sector analysts, bankers and industry professionals.

About SYNCELL Inc.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

CONTACT:
Shuyi Liao
SYNCELL, Inc.
Phone +886-2-77505632
Info@syncell.com
Follow SYNCELL on LinkedIn at SYNCELL INC. and tag your posts with #syncell or #microscoop"